The SARS‐CoV‐2 main protease (Mpro): Structure, function, and emerging therapies for COVID‐19

Q Hu, Y Xiong, GH Zhu, YN Zhang, YW Zhang… - MedComm, 2022 - Wiley Online Library
The main proteases (Mpro), also termed 3‐chymotrypsin‐like proteases (3CLpro), are a
class of highly conserved cysteine hydrolases in β‐coronaviruses. Increasing evidence has …

Bench-to-bedside: Innovation of small molecule anti-SARS-CoV-2 drugs in China

L Yang, Z Wang - European journal of medicinal chemistry, 2023 - Elsevier
The ongoing COVID-19 pandemic has resulted in millions of deaths globally, highlighting
the need to develop potent prophylactic and therapeutic strategies against SARS-CoV-2 …

SARS-CoV-2 main protease drug design, assay development, and drug resistance studies

B Tan, R Joyce, H Tan, Y Hu… - Accounts of chemical …, 2022 - ACS Publications
Conspectus SARS-CoV-2 is the etiological pathogen of the COVID-19 pandemic, which led
to more than 6.5 million deaths since the beginning of the outbreak in December 2019. The …

Small molecules in the treatment of COVID-19

S Lei, X Chen, J Wu, X Duan, K Men - Signal transduction and targeted …, 2022 - nature.com
The outbreak of COVID-19 has become a global crisis, and brought severe disruptions to
societies and economies. Until now, effective therapeutics against COVID-19 are in high …

Bioactive natural products in COVID-19 therapy

Z Wang, N Wang, L Yang, X Song - Frontiers in Pharmacology, 2022 - frontiersin.org
The devastating COVID-19 pandemic has caused more than six million deaths worldwide
during the last 2 years. Effective therapeutic agents are greatly needed, yet promising magic …

The key role of lysosomal protease cathepsins in viral infections

M Scarcella, D d'Angelo, M Ciampa, S Tafuri… - International journal of …, 2022 - mdpi.com
Cathepsins encompass a family of lysosomal proteases that mediate protein degradation
and turnover. Although mainly localized in the endolysosomal compartment, cathepsins are …

Discovery of novel SARS-CoV-2 3CL protease covalent inhibitors using deep learning-based screen

L Wang, Z Yu, S Wang, Z Guo, Q Sun, L Lai - European journal of medicinal …, 2022 - Elsevier
Abstract SARS-CoV-2 3CL protease is one of the key targets for drug development against
COVID-19. Most known SARS-CoV-2 3CL protease inhibitors act by covalently binding to …

Beyond the vaccines: a glance at the small molecule and peptide-based anti-COVID19 arsenal

K Nepali, R Sharma, S Sharma, A Thakur… - Journal of Biomedical …, 2022 - Springer
Unprecedented efforts of the researchers have been witnessed in the recent past towards
the development of vaccine platforms for the control of the COVID-19 pandemic. Albeit …

[HTML][HTML] Discovery of lead natural products for developing pan-SARS-CoV-2 therapeutics

J Pérez-Vargas, T Shapira, AD Olmstead, I Villanueva… - Antiviral research, 2023 - Elsevier
The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), remains a global public health crisis. The reduced efficacy of therapeutic …

Identification of natural products inhibiting SARS-CoV-2 by targeting viral proteases: a combined in silico and in vitro approach

A Wasilewicz, B Kirchweger, D Bojkova… - Journal of Natural …, 2023 - ACS Publications
In this study, an integrated in silico–in vitro approach was employed to discover natural
products (NPs) active against SARS-CoV-2. The two SARS-CoV-2 viral proteases, ie, main …